Behavioural models for the characterisation of established and innovative antidepressant agents

Therapie

Volumn 60, Issue 5, 2005, Pages 477-484

  Dekeyne, Anne ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Antidepressant; Drug discrimination; Marble burying; Social interaction

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE UPTAKE INHIBITOR; FLUVOXAMINE; GR 226206; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PRAZOSIN; REBOXETINE; S 33005; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VOFOPITANT;

ANHEDONIA; ANXIETY; BEHAVIOR; BODY WEIGHT DISORDER; COGNITIVE DEFECT; COMORBIDITY; COMPARATIVE STUDY; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TARGETING; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FOOD INTAKE; GERBIL; HOPELESSNESS; HUMAN; IMPULSIVENESS; NERVOUSNESS; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; PSYCHOPHARMACOLOGY; REVIEW; RODENT; SEXUAL DYSFUNCTION; SLEEP DISORDER; SOCIAL BEHAVIOR; SYMPTOMATOLOGY; TRANQUILIZING ACTIVITY; ANIMAL; CLASSIFICATION; DISEASE MODEL; MOUSE; PSYCHOLOGICAL MODEL;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HUMANS; MICE; MODELS, PSYCHOLOGICAL; RODENTIA;

EID: 33645240467     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005068     Document Type: Article

References (58)

1. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-45
2. O'Neil MF, Moore NA. Animal models of depression: are there any? Hum Psychopharmacol Clin Exp 2003; 18: 239-54
3. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol 2002; 13: 169-88
4. Rupniak NMJ. Animal models of depression: challenges from a drug development perspective. Behav Pharmacol 2003; 14: 385-90
5. Millan MJ, Dekeyne A, Papp M, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther 2001; 298: 581-91
6. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997; 134: 319-29
7. Henkel V, Bussfeld P, Möller HJ, et al. Cognitive-behavioural theories of helplessness/hopelessness: valid models of depression? Eur Arch Psychiatry Clin Neurosci 2002; 252: 240-9
8. Murphy DL, Mueller EA, Hill JL, et al. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 1989; 98: 275-82
9. Kahn RS, Wetzler S. M-chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991; 30: 1139-66
10. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997; 74: 299-316
11. Dekeyne A, Gobert A, Auclair A, et al. Differential modulation of efficiency in a food-rewarded 'differential reinforcement of low rate' 72-second schedule in rats by norepinephrine and serotonin reuptake inhibitors. Psychopharmacology 2002; 162: 156-67
12. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5
13. 1) antagonists. Trends Pharmacol Sci 1999; 20: 485-90
14. 1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 2001; 12: 497-508
15. Spooren WPJM, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl- 6(phenylethynyl) pyridine in rodents. J Pharmacol Exp Ther 2000; 295: 1267-75
16. 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model. Jpn J Pharmacol 2002; 90: 197-200
17. Chaki S, Hirota S, Funakoshi T, et al. Anxiolytic-like and antidepressant-like activities of MCL01029 (1-[(S)-2-(4-fluorophenyl)-2-(4- isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphtalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J Pharmacol Exp Ther 2003; 304: 818-26
18. Shimazaki T, Iijima M, Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 2004; 501: 121-5
19. 1) receptor antagonists. Neuropharmacology 2002; 42: 677-84
20. McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990; 39: 136-53
21. Mundo E, Maina G, Uslenghi C. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2000; 15: 69-76
22. Mir S, Taylor D. The adverse effects of antidepressants. Curr Opin Psychiatry 1997; 10: 88-94
23. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999; 60 Suppl. 4: 4-11
24. Goudie AJ, Leathley MJ. Drug discrimination assays. In: Shagal A, editor. Behavioural neuroscience. Oxford: University Press, 1993: 145-67
25. Goudie AJ, Smith JA. Discriminative stimulus properties of antipsychotics. Pharmacol Biochem Behav 1999; 64: 193-201
26. Dekeyne A, Millan MJ. Discriminative stimulus properties of antidepressant agents: a review. Behav Pharmacol 2003; 14: 391-407
27. Marona-Lewicka D, Nichols DE. Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology 1998; 138: 67-75
28. 2C are involved in the discriminative stimulus effects of citalopram in rats. Psychopharmacology 1999; 142: 432-4
29. Dekeyne A, Gobert A, Iob L, et al. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats. Psychopharmacology 2001; 154: 213-8
30. Dekeyne A, Iob L, Millan MJ. Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology 2001; 153: 389-92
31. 1 antagonist, GR205.171 [abstract]. Eur Neuropsychopharmacol 2004; 14 Suppl. 3: S200
32. Millan MJ, Gobert A, Girardon S, et al. Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs dopamine and noradrenaline. Eur J Pharmacol 1999; 364: 147-50
33. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005; 60 (5): 441-60
34. Quested DJ, Sargent PA, Cowen PJ. SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology 1997; 133: 305-8
35. 1A receptor antagonist, WAY 100,635, in the rat. Neuropharmacology 2000; 39: 1222-36
36. 2C receptors and their atypical regulation properties. Life Sci 2003; 72: 2429-49
37. 2C/2B receptor function. Neuropharmacology 1994; 33: 1581-8
38. 2C receptors. Br J Pharmacol 1998; 124: 1781-7
39. 2C receptors. Neuropharmacology 2000; 39: 1114-7
40. Brocco M, Dekeyne A, Veiga S, et al. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake: a pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 2002; 71: 667-80
41. 2C receptors in affective disorders. Expert Opin Investig Drugs 1998; 7: 1587-99
42. 2C receptors. J Pharmacol Exp Ther 2000; 295: 1120-6
43. 2C receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol 2001; 11: 145-52
44. Banasr M, Hery M, Printemps R, et al. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004; 29: 450-60
45. 1B-adrenoceptors in the motor activity and spontaneous movement of mice. Neuropharmacology 2001; 40: 254-61
46. 1- adrenergic neurotransmission in necessary for behavioral activation to environmental change in mice. Neuroscience 1999; 94: 1245-52
47. 2A systems. J Neural Transm 2000; 107: 1345-9
48. 1-adrenergic system. Neuropharmacology 2001; 41: 360-8
49. 1 receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 2001; 76: 1949-54
50. 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem 2004; 89: 54-63
51. Gardier A. Compréhension du mécanisme d'action des antidépresseurs anciens et nouveaux : apports des modèles de souris génétiquement modifiées en pharmacologie in vivo. Therapie 2005; 60 (5): 469-76
52. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244
53. Rouillon F. Long-term therapy of generalized anxiety disorders. Eur Psychiatry 2004; 19: 96-101
54. Brawman-Mintzer O, Yonkers KA. New trends in the treatment of anxiety disorders. CNS Spectr 2004; 9: 19-27
55. 1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 2001; 915: 170-5
56. Dekeyne A, Millan MJ. Short- and long-term influence of the dual serotonin/nor-adrenaline reuptake inhibitors ('SNRIs'), venlafaxine and S33005, upon anxious behaviour in rats [abstract P460.8]. Soc Neurosci Abstr 2003
57. Griebel G, Moreau JL, Jenck F, et al. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 1994; 113: 463-70
58. 1 receptor antagonist GR205171 in the social interaction test in gerbils [abstract]. Behav Pharmacol 2003; 14 Suppl. 1: S23